Protective effect of metformin in lung cancer patients. Print this page
Sub-category:
Prognostic Factors
Category:
Tumor Biology
Meeting:
2009 ASCO Annual Meeting
Session Type and Session Title:
This abstract will not be presented at the 2009 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract No:
e22063
Citation:
J Clin Oncol 27, 2009 (suppl; abstr e22063)
Author(s):
B. Gagnon, M. Roseman, G. Kasymjanova, N. MacDonald, H. Kreisman, D. Small; McGill University, Montreal, QC, Canada; SMBD-Jewish General Hospital, Montreal, QC, Canada
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Abstract:
Background: Over the past decade, dozens of studies have shown that metformin not only decreases mortality in diabetics, it also significantly reduces CRP and reduces the risks of cancer in rodent and human cell lines. We report on the survival of lung cancer patients concomitantly exposed to metformin in our community-based program. Methods: 850 patients undergoing treatment from a prospectively collected pulmonary oncology database of the SMBD-Jewish General Hospital over an 8-year period were analyzed. Pilot observational study of survival was performed using Cox regression model. The factors that were included in the model were age, gender, stage, histology and metformin use. Results: 850 patients (F: M=375:475; mean age of 66) were diagnosed since 2000 and followed in pulmonary oncology outpatient clinic for NSCLC. 523 (62%) of those patients were diagnosed with adenocarcinoma; 488 (57%) were stage IIIB with pleural effusion/IV. 79(9%) patients were receiving treatment with metformin for their comorbid type 2 diabetes. The Cox regression analysis demonstrated that age, gender, stage and use of metformin were significant prognostic factors for survival. The use of metformin is associated with a 37% (HR 1.37; CI 1.01-1.84) (p=0.039) increase in survival. Conclusions: Thus, the result obtained from our model suggests that use of metformin may be associated with better survival of lung cancer patients. As this is a pilot study, we will consider alternative explanations.
|
显身卡
